FDA Approved: DAYPRO — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

FDA approved a supplemental labeling application for DAYPRO (oxaprozin) submitted by Pfizer Laboratories Div Pfizer Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis
• Rheumatoid Arthritis

Drugs mentioned

• DAYPRO (oxaprozin)

Snippet

SUPPL AP for DAYPRO (OXAPROZIN)